Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.

Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Cost-Benefit Analysis
Humans
Medicare
Melanoma
Proto-Oncogene Proteins B-raf
Quality-Adjusted Life Years
Skin Neoplasms
United States

authors with profiles

Thomas F. Gajewski